Does Treating Obstructive Sleep Apnea in Obese Canadian Youth Improve Blood Sugar Control? (IMPACT Obesity)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2011 by Katz, Sherri Lynne, M.D..
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Canadian Institutes of Health Research (CIHR)
Information provided by:
Katz, Sherri Lynne, M.D.
ClinicalTrials.gov Identifier:
NCT01116375
First received: April 30, 2010
Last updated: June 15, 2011
Last verified: June 2011
  Purpose

To determine whether, in obese children with moderate-severe Obstructive Sleep Apnea who are prescribed Positive Airway Pressure(PAP) therapy, increased hours of PAP usage per night over a one-year period is associated with a greater improvement in HOMA-IR


Condition
Obesity
Obstructive Sleep Apnea

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Does Treating Obstructive Sleep Apnea in Obese Canadian Youth Improve Blood Sugar Control? A Multi-Centered Prospective Cohort Study

Resource links provided by NLM:


Further study details as provided by Katz, Sherri Lynne, M.D.:

Primary Outcome Measures:
  • HOMA-IR [ Time Frame: 1 year after start of PAP therapy ] [ Designated as safety issue: No ]
    Euglycemichyperinsulinemic clamp technique is the gold standard measurement technique for insulin resistance however, invasive and rarely used in clinical practice. A surrogate is the homeostasis model assessment (HOMA) formula for insulin resistance (HOMA-IR) Thus, lower HOMA values indicate higher insulin sensitivity. The estimate obtained with HOMA correlates well with measures of insulin resistance obtained from obese and non-obese children and adolescents with the clamp technique


Secondary Outcome Measures:
  • Systemic Hypertension [ Time Frame: 1 year after start of treatment with PAP ] [ Designated as safety issue: No ]
    Systemic hypertension,will be measured with 24-hour ABPM at baseline and 1 year. Summary measures for each of the day and night periods include average systolic and diastolic BP, and systolic and diastolic BP loads, as well as % nocturnal dipping. These summary measures have been shown to predict important outcomes including left ventricular hypertrophy, cardiovascular events, and death more accurately than casual BP measures

  • Heart rate and heart rate variability [ Time Frame: 1 year after the start of PAP therapy ] [ Designated as safety issue: No ]
    Heart rate and heart rate variability will be analyzed from electrocardiography (EKG) data acquired during polysomnography performed at baseline and 1 year. EKG is more accurate than pulse oximetry to measure high- and low-frequency variability in heart rate and thus is the gold standard for obtaining these measures during sleep.We will focus on the RR interval as a measure of heart rate. Both time-domain components and frequency-domain components will be considered as measures of heart rate variability. We will use normative values as derived by Massin et al.

  • hsCRP [ Time Frame: 1 year after start of PAP therapy ] [ Designated as safety issue: No ]
    Blood samples obtained at baseline, 6 months and 1 year will be assessed for levels of CRP, a protein which is released during the chronic inflammation underlying atherosclerosis. Compared with the standard CRP test, the hsCRP assay can detect lower protein concentrations with greater sensitivity and achieves better specificity for predicting vascular events

  • Conners' Parent and Teacher Rating Scales [ Time Frame: 1 Year fter the start fo PAP therapy ] [ Designated as safety issue: No ]
    The Conners' Parent and Teacher Rating Scales have demonstrated excellent reliability and validity. These commonly used questionnaires rely on observer ratings to assess attention deficit/hyperactivity disorder (ADHD) and evaluate problem behaviour in children and adolescents. We will use the Revised Short version which contains 27 items with scales measuring oppositional behaviour, cognitive problems/inattention and symptoms of ADHD

  • Child Behavior Checklist [ Time Frame: 1 year after start of PAPA therapy ] [ Designated as safety issue: No ]
    The Child Behavior Checklist is one of the most widely-used standardized measures in child psychology for evaluating maladaptive behavioural and emotional problems in children Specifically, this parent-report questionnaire contains 118 items aimed at assessing the frequency of observed internalizing (i.e. anxious, depressive, and overcontrolled) and externalizing (i.e. aggressive,hyperactive, noncompliant, and undercontrolled) behaviors.

  • Pediatric Quality of Life Inventory (PEDS-QL) [ Time Frame: 1 Yaer after start of PAP therapy ] [ Designated as safety issue: No ]
    The PEDS-QL is a 23-item test designed to evaluate levels of functioning in 4 areas of health: physical, emotional, social and scholastic. This tool has demonstrated excellent reliability and validity and is frequently used to assess pediatric quality of life.


Estimated Enrollment: 54
Study Start Date: June 2010
Estimated Study Completion Date: September 2012
Estimated Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts
Obese children with OSA
To determine whether, in obese children with moderate-severe OSA who are prescribed PAP therapy, increased hours of PAP usage per night over a one-year period is associated with a greater improvement in HOMA-IR

Detailed Description:

Rationale: The five-fold increase in prevalence of childhood obesity in Canada over the last 15 years has led to an increasing number of pediatric cases of obesity-related obstructive sleep apnea (OSA). Not only is the prevalence of OSA significantly higher among obese children compared with the general population, but in this group, routine treatment by adenotonsillectomy has a much lower cure rate. Instead, Positive Airway Pressure (PAP) treatment is usually prescribed. Other complications of obesity are also increasingly recognized in children, including metabolic disturbances with insulin resistance (IR). This is particularly concerning, since IR is an identified surrogate measure of future obesity-related sequelae, such as diabetes, dyslipidemia, cardiovascular disease (including hypertension, and heart rate disturbances), inflammation and impaired quality of life. Of particular interest, the IR related to obesity can be exacerbated by OSA and the severity of IR correlates with the severity of OSA. IR is measured using a homeostasis model assessment of insulin resistance (HOMA-IR) and is calculated from fasting blood glucose and insulin levels. In obese adults with OSA, HOMA-IR, as well as cardiovascular and other metabolic markers, has been shown to improve following PAP therapy. Such a study has not been done in children. We hypothesize that PAP treatment for obese children with moderate-severe OSA will improve markers of obesity-related disease.

Primary Objective: To determine whether, in obese children with moderate-severe OSA who are prescribed PAP therapy, increased hours of PAP usage per night over a one-year period is associated with a greater improvement in HOMA-IR. Secondary Objectives: To determine whether increased hours of PAP usage per night is associated with a greater improvement in the following outcomes: 1) sympathetic nervous system activation (systolic and diastolic hypertension, nocturnal hypertension, heart rate and heart rate variability); 2) inflammation 3) neurobehavioral and quality of life measures. Methods: Study design: prospective multi-centre cohort study. Study Population: Obese children (body mass index (BMI) ≥ 95th %ile for age and sex) 8-17 years old with moderate-severe OSA will be recruited for this study from four pediatric tertiary care centres across Canada. As per current standard of care, those children with moderate-severe OSA, defined as ≥ 10 obstructive events per hour on polysomnography, will be prescribed PAP treatment. Sample Size: We expect a medium effect size (0.5); therefore 10 subjects per parameter tested (n=4) in the regression model and 25% attrition requires the recruitment of 54 subjects. Measurements will be made at baseline and 12 months. Data collection will include HOMA-IR, 24-hr blood pressure measurements, electrocardiogram for heart rate and heart rate variability, C-reactive protein as a marker of inflammation, neurobehavioral/quality of life measures (Conners parent and teacher scales, Child Behavior Checklist and Pediatric Quality of Life Inventory) and physical activity questionnaire (Habitual Activity Estimation Scale (HAES)). Data Analysis: Multivariate linear regression analyses will be performed for our primary and secondary outcomes. Our dependent variable will be change in HOMA-IR; our primary independent variable will be average number of hours/night of PAP usage. Adjustment variables will be change in BMI %ile, pubertal stage (Tanner stage 1-2 vs.

3-5), and change in HAES. Similar analyses will be performed for our secondary outcomes.

Importance: Treatment of obesity-related OSA in adults has been shown to reduce morbidity and mortality. Our study is uniquely poised and timely, as it will be the first to examine the impact of PAP therapy in children on measures of insulin resistance and other obesity-related conditions. It will raise awareness of co-morbidities of obesity and OSA in childhood and support early intervention, before irreversible end-organ damage has occurred.

  Eligibility

Ages Eligible for Study:   8 Years to 16 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Obese children (body mass index (BMI) ≥ 95th %ile for age and sex) 8-17 years old with moderate-severe OSA will be recruited for this study from four pediatric tertiary care centres across Canada. As per current standard of care, those children with moderate-severe OSA, defined as ≥ 10 obstructive events per hour on polysomnography, will be prescribed PAP treatment.

Criteria

Inclusion Criteria:

  • Age 8 to 16 years
  • Obesity, defined as body mass index greater than or equal to the 95th percentile for gender and age (2000 CDC Growth Charts for US)
  • Moderate to severe OSA diagnosed on polysomnography, for which PAP therapy (continuous positive airway pressure or bi-level positive airway pressure) is prescribed by a physician. Overnight laboratory polysomnography, the gold standard for assessment of OSA115 and titration of PAP, will be performed and scored by a certified sleep technician, according to the American Academy of Sleep Medicine recommendations. Moderate to severe OSA will be defined as an obstructive apneahypopnea index (OAHI) of greater than or equal to 10 apneas or hypopneas per hour. Although no strict guidelines for defining severity of OSA in children exist, the definition for this study was derived by a consensus of pan-Canadian pediatric sleep medicine experts.
  • Parents/guardians and children must also be fluent in English or French.

Exclusion Criteria:

  • craniofacial anomalies other than tonsillar and adenoid enlargement118, 119
  • central nervous system lesions
  • neuromuscular, neurological, or genetic syndromes
  • congenital heart disease and/or diagnosed ventricular dysfunction
  • chronic respiratory disease with the exception of asthma
  • use of oral or intravenous corticosteroids within the past 3 months (as this would affect the primary outcome).
  • prior exposure to PAP therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01116375

Contacts
Contact: Sherri L Katz, MD 613 737 7600 ext 2956 skatz@cheo.on.ca
Contact: Lynda M Hoey, RN 613 737 7600 ext 4109 lhoey@cheo.on.ca

Locations
Canada, Alberta
Alberta Children's Hospital Recruiting
Calgary, Alberta, Canada
Contact: Valerie Kirk, MD         
Stollery Children's Hospital Recruiting
Edmonton, Alberta, Canada
Contact: Maisha Witmans, MD         
Canada, Ontario
Childrens Hospital of Eastern Ontario Recruiting
Ottawa, Ontario, Canada
Contact: Sherri Katz, MD    613 737 7600 ext 2956    skatz@cheo.on.ca   
Canada, Quebec
Montreal Childrens Hospital Recruiting
Montreal, Quebec, Canada
Contact: Evelyn Constantin, MD         
Sponsors and Collaborators
Katz, Sherri Lynne, M.D.
Canadian Institutes of Health Research (CIHR)
Investigators
Principal Investigator: Evelyn Constantin, MD Montreal Children's Hospital of the MUHC
Principal Investigator: Sherri L Katz, md Childrens Hospital of Eatern Ontario
  More Information

No publications provided

Responsible Party: Katz, Sherri Lynne, M.D., Childrens Hospital of Eastern Ontario
ClinicalTrials.gov Identifier: NCT01116375     History of Changes
Other Study ID Numbers: 1234
Study First Received: April 30, 2010
Last Updated: June 15, 2011
Health Authority: Canada: Ethics Review Committee

Keywords provided by Katz, Sherri Lynne, M.D.:
Obesity
OSA
PAP therapy

Additional relevant MeSH terms:
Apnea
Obesity
Sleep Apnea Syndromes
Sleep Apnea, Obstructive
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Signs and Symptoms
Overnutrition
Nutrition Disorders
Overweight
Body Weight
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Disorders
Nervous System Diseases

ClinicalTrials.gov processed this record on August 21, 2014